Massachusetts Financial Services Co. MA Purchases 14,226 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Massachusetts Financial Services Co. MA grew its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 522,375 shares of the company’s stock after purchasing an additional 14,226 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.24% of Prelude Therapeutics worth $1,990,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Acadian Asset Management LLC grew its position in Prelude Therapeutics by 42.7% during the first quarter. Acadian Asset Management LLC now owns 22,110 shares of the company’s stock worth $104,000 after buying an additional 6,615 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Prelude Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock worth $4,821,000 after purchasing an additional 10,143 shares during the last quarter. Kennedy Capital Management LLC purchased a new stake in Prelude Therapeutics in the first quarter valued at approximately $119,000. Pale Fire Capital SE lifted its position in Prelude Therapeutics by 106.6% during the fourth quarter. Pale Fire Capital SE now owns 63,581 shares of the company’s stock valued at $271,000 after purchasing an additional 32,800 shares during the last quarter. Finally, Boxer Capital LLC grew its stake in Prelude Therapeutics by 2.9% in the 4th quarter. Boxer Capital LLC now owns 2,568,287 shares of the company’s stock worth $10,967,000 after buying an additional 73,269 shares in the last quarter. Institutional investors own 79.72% of the company’s stock.

Prelude Therapeutics Stock Performance

Shares of Prelude Therapeutics stock opened at $2.55 on Monday. Prelude Therapeutics Incorporated has a 52-week low of $1.66 and a 52-week high of $6.80. The company has a fifty day moving average of $5.10 and a 200-day moving average of $4.47. The stock has a market capitalization of $140.30 million, a price-to-earnings ratio of -1.36 and a beta of 1.52.

Prelude Therapeutics (NASDAQ:PRLD) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46). On average, equities research analysts forecast that Prelude Therapeutics Incorporated will post -1.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays cut shares of Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research report on Thursday, June 20th. JMP Securities reaffirmed a “market outperform” rating and set a $7.00 price target on shares of Prelude Therapeutics in a research note on Monday, September 16th. Finally, HC Wainwright upgraded Prelude Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.